A Phase 4 interventional study of De-escalation strategy and Conventional strategy in Acute Myocardial Infarction, sponsored by Dong-A University. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-01.
Sponsored by Dong-A University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Myocardial Infarction with a site in Korea, Republic of — 21 open to participants now, 26 under way, 5 of them phase 3. Myocardial Infarction · Korea, Republic of.
Among the 99 studies in Myocardial Infarction with a site in Korea, Republic of, this one is the 28th largest by planned enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 in phase 4, reaches primary completion later than 8 of the 25 other live ones, and was the 69th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →21 of the 99 studies in Myocardial Infarction with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
CHA University · Sites in Korea, Republic of
Ages 18+
Seoul National Hospital · Sites in Korea, Republic of
Ages 19–80
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 25 · Phase 4 22
First in 2001; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,312 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 820 across the 73 interventional studies, 1,537 across the 25 observational. Of the 55 that completed or were terminated, 14 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 99 have an industry lead sponsor. The 10 most frequent:
Dong-A University is the lead sponsor of 33 studies on the registry; 1 is open to participants now.
Dong-A University has 3 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
4 of the studies in Myocardial Infarction with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT03412435Seung-Jung ParkAsan Medical Center Myocardial Infarction Registry | 2026-12-31 |
| NCT04755387Dong-A UniversityTicagrelor De-escalation Strategy in AMI Patients | 2027-01-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 99 studies in Myocardial Infarction with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. The EASTYLE trial will evaluate a hybrid DAPT de-escalation strategy (reduced-dose ticagrelor, followed by aspirin early discontinuation) in AMI patients, compared with a conventional DAPT strategy.
In ACS patients undergoing percutaneous coronary intervention, conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y12 inhibitor (prasugrel or ticagrelor) for 12 months. Although this approach reduces ischaemic risk, patients are exposed to a substantial risk of bleeding during the stabilized period. Strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT duration. Abbreviation of DAPT duration after 1-6 months, followed by monotherapy with aspirin or a P2Y12 inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk. Either strategy requires assessment of the ischaemic and bleeding risks of each individual. Previous clinical and laboratory evidence demonstrates that a conventional-dose of ticagrelor has a potent antiplatelet effect, which appears to have a potential to increase the risk of bleeding during the stabilized period. Adjunctive use of aspirin to P2Y12 inhibitor would be important to protect the risk of thrombotic events in AMI patients, which use has a limited benefit with increased bleeding rate during the the stabilized period.
The EASTYLE trial will evaluate clinical benefit of step-down de-escalation DAPT strategy including downgrading of P2Y12 inhibition (from 90 mg to 60 mg ticagrelor at 1 month post-PCI) and abbreviation of DAPT duration (aspirin discontinuation at 3 months post-PCI), compared with a conventional DAPT strategy in AMI patients. This trial will support that the optimal platelet inhibition would be attenuated over time even in AMI patients. The result will make a big step toward precision medicine in the field of antiplatelet treatment in AMI patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PCI \~ 1 month: ticagrelor 90 mg twice daily + aspirin 100 mg once daily 1 \~ 3 months: ticagrelor 60 mg twice daily + aspirin 100 mg once daily 3 \~ 12 months: ticagrelor 60 mg twice daily
Drug: De-escalation strategy
PCI \~ 12 months: ticagrelor 90 mg twice daily + aspirin 100 mg once daily
Drug: Conventional strategy
De-escalation strategy indicates conventional DAPT (ticagrelor 90 mg twice daily + aspirin 100 mg once daily) for 1 month, followed by de-escalation DAPT (ticagrelor 60 mg twice daily + aspirin 100 mg once daily) between 1 and 3 months. Between 3 and 12 months, patients will be treated with ticagrelor monotherapy (ticagrelor 60 mg twice daily).
Also known as: Ticagrelor 60 mg, aspirin early discontinuation
Conventional stratetgy indicates conventional DAPT including ticagrelor 90 mg twice daily and aspirin 100 mg once daily during 12 months.
Also known as: Ticagrelor 90 mg, DAPT
Primary endpoint (NACE)
MACCE (all-cause death, non-fatal myocardial infarction, stent thrombosis or non-fatal stroke) + major bleeding (BARC type 2, 3, or 5 bleeding)
Time frame: 12 months
Major adverse cardiac and cerebrovascular events (MACCE)
all-cause death, non-fatal myocardial infarction, stent thrombosis or non-fatal stroke
Time frame: 12 months
Bleeding events
BARC type 2, 3 or 5 bleeding; BARC 3 or 5 bleeding; TIMI major or minor bleeding; GUSTO severe or moderate bleeding; ISTH major bleeding
Time frame: 12 months
All-cause death
any mortality
Time frame: 12 months
CV death
Death related CV system
Time frame: 12 months
MI
Myocardial infarction
Time frame: 12 months
Stent thrombosis
definite or probable stent thrombosis by Academic Research Consortium (ARC) definition
Time frame: 12 months
Ischemic stroke
Stroke
Time frame: 12 months
Cardiac death, or MI
Coronary thrombotic events
Time frame: 12 months
Cardiac death, MI or stent thrombosis
Coronary thrombotic events
Time frame: 12 months
Cardiovascular death, MI or stroke
MACE
Time frame: 12 months
TLR
target lesion revascularization
Time frame: 12 months
TVR
target vessel revascularization
Time frame: 12 months
Any revascularization
Re-PCI during follow-up
Time frame: 12 months
Type of AMI
STEMI vs. NSTEMI
Time frame: 12 months
HBR
presence of HBR (high bleeding risk) criteria
Time frame: 12 months
DM
presence of diabetes mellitus
Time frame: 12 months
CKD
presence of chronic kidney disease
Time frame: 12 months
Anemia
presence of anemia
Time frame: 12 months
Gender
Male vs. female
Time frame: 12 months
Age
Old vs. young age (65 yo, 75 yo)
Time frame: 12 months
Complex PCI
Presence of complex PCI
Time frame: 12 months
GDMT
Presence of guideline-directed medical therapy
Time frame: 12 months
Type of statin
Rosuvastatin vs. other statins
Time frame: 12 months
CHF
Presence of congestive heart failure
Time frame: 12 months
PAD
Presence of peripheral artery disease
Time frame: 12 months
PFT
VerifyNow assy
Time frame: 12 months
Predictors of MACCE
Clinical impact of de-esclation strategy on MACCE
Time frame: 12 months
Predictors of maor bleeding
Clinical impact of de-esclation strategy on major bleeding
Time frame: 12 months
Plan to share: Undecided
Started Mar 2023 (actual). Primary completion is estimated for Jan 2027, 45 months after the start.
Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's planned 45 months is close to that.
Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dong-A University